Viva Biotech buys back 1.20 million shares; cumulative 13.42 million repurchased since mandate

Bulletin Express05-21

Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD 1.72 million. All repurchased shares are designated for cancellation.

The latest transaction lifts the aggregate number of shares bought back under the mandate approved on 12 June 2025 to 13.42 million, representing 0.63 % of the company’s issued share capital at the time the mandate was granted. The mandate permits a maximum repurchase of 212.84 million shares.

Despite the ongoing buybacks, the company’s issued share capital remained unchanged at 2.13 billion shares as of the close on 21 May 2026 because the repurchased shares had not yet been cancelled. Viva Biotech is subject to a moratorium on new share issues until 20 June 2026, in accordance with Hong Kong listing rules following the repurchase activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170644259?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170644259","market":"us","top_or_hot":-1,"title":"Viva Biotech buys back 1.20 million shares; cumulative 13.42 million repurchased since mandate","media":"Bulletin Express","content":"<p>Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD 1.72 million. All repurchased shares are designated for cancellation.</p>\n<p>The latest transaction lifts the aggregate number of shares bought back under the mandate approved on 12 June 2025 to 13.42 million, representing 0.63 % of the company’s issued share capital at the time the mandate was granted. The mandate permits a maximum repurchase of 212.84 million shares.</p>\n<p>Despite the ongoing buybacks, the company’s issued share capital remained unchanged at 2.13 billion shares as of the close on 21 May 2026 because the repurchased shares had not yet been cancelled. Viva Biotech is subject to a moratorium on new share issues until 20 June 2026, in accordance with Hong Kong listing rules following the repurchase activity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech buys back 1.20 million shares; cumulative 13.42 million repurchased since mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech buys back 1.20 million shares; cumulative 13.42 million repurchased since mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-21 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD 1.72 million. All repurchased shares are designated for cancellation.</p>\n<p>The latest transaction lifts the aggregate number of shares bought back under the mandate approved on 12 June 2025 to 13.42 million, representing 0.63 % of the company’s issued share capital at the time the mandate was granted. The mandate permits a maximum repurchase of 212.84 million shares.</p>\n<p>Despite the ongoing buybacks, the company’s issued share capital remained unchanged at 2.13 billion shares as of the close on 21 May 2026 because the repurchased shares had not yet been cancelled. Viva Biotech is subject to a moratorium on new share issues until 20 June 2026, in accordance with Hong Kong listing rules following the repurchase activity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1170644259","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170644259","pubTimestamp":1779360220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物回购120万股；授权以来累计回购1342万","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD 1.72 million. All repurchased shares are designated for cancellation.\nThe latest transaction lifts the aggregate number of shares bought back under the mandate approved on 12 June 2025 to 13.42 million, representing 0.63 % of the company’s issued share capital at the time the mandate was granted. The mandate permits a maximum repurchase of 212.84 million shares.\nDespite the ongoing buybacks, the company’s issued share capital remained unchanged at 2.13 billion shares as of the close on 21 May 2026 because the repurchased shares had not yet been cancelled. Viva Biotech is subject to a moratorium on new share issues until 20 June 2026, in accordance with Hong Kong listing rules following the repurchase activity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170644259","isCrawlerRequest":true}